Overview

Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients

Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
Phase:
Phase 1
Details
Lead Sponsor:
Genfit
Treatments:
Nitazoxanide